CDR2 and paraneoplastic neurologic syndrome: However, anti-Hu antibodies are present only in a limited number of individuals (16%), whereas only 1–3% develop paraneoplastic neurological syndromes, similar to the incidence of anti-Yo related paraneoplastic neurological syndromes in women with gynecological tumors [34,35,36].